RZLT

Rezolute Inc.

RZLT 4 | $2.86 -19.21% -23.78% 930K

(0.0% 1d) (87.3% 1m) (67.0% 1y) (0.0% 2d) (0.0% 3d) (9.3% 7d) (NaN% volume)
Earnings Calendar: 2024-02-09
Market Cap: $ 114,765,070
http://www.rezolutebio.com
Sec Filling | Patents | 23 employees

(US) Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

insulin antibody diabetes diabetic macular metabolic injection

add to watch list Paper trade email alert is off

Press-releases

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 2.61% | O: 0.87% H: 0.0% C: 0.0%
endocrine meeting study

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 98.88% | O: 3.93% H: 5.41% C: -2.97%
rz358 cell treatment hypoglycemia tumor potential

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Published: 2024-02-13 (Crawled : 21:00) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 224.77% | O: -1.83% H: 15.89% C: 15.89%
business update results

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Published: 2024-01-24 (Crawled : 13:00) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 247.06% | O: 2.94% H: 4.76% C: 3.33%
NEPH | $2.09 -0.96% 1.2K

Health Technology

| -40.79% | O: 0.0% H: 3.12% C: 0.57%
financial

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Published: 2024-01-23 (Crawled : 13:00) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 261.22% | O: 2.04% H: 9.0% C: 2.0%
rz358 innovation group treatment designation hypoglycemia

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Published: 2023-12-14 (Crawled : 13:00) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 288.88% | O: 3.26% H: 0.0% C: -6.61%
rz358 study

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Published: 2023-12-13 (Crawled : 13:00) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 321.43% | O: 7.13% H: 1.16% C: 1.16%
macular study diabetic

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)Plans to report topline data mid-second quarter 2024
Published: 2023-12-13 (Crawled : 15:30) - biospace.com/
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 321.43% | O: 7.13% H: 1.16% C: 1.16%
report macular topline study diabetic

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 359.74% | O: 2.27% H: 1.59% C: -1.61%
report biotech

Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
Published: 2023-11-17 (Crawled : 13:00) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

| 337.85% | O: -0.99% H: 4.51% C: 2.16%
day

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000912282-24-000331	4	2024-03-29	2024-03-28	Buy	P	500	1076
0000912282-24-000283	4	2024-03-19	2022-07-22	Buy	P	3157895	5942617
0000912282-24-000283	4	2024-03-19	2021-10-15	Buy	P	769231	2784722
0000912282-24-000274	4	2024-03-19	2024-03-15	Buy	P	20000	20000
0000912282-24-000270	4	2024-03-18	2024-03-14	Buy	P	10000	10000